Collegium Pharmaceutical (COLL) Competitors $26.79 +0.01 (+0.04%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$26.80 +0.02 (+0.06%) As of 04/25/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock COLL vs. RNA, ACLX, RARE, ZLAB, AKRO, MRUS, MOR, SRRK, PTGX, and CRNXShould you be buying Collegium Pharmaceutical stock or one of its competitors? The main competitors of Collegium Pharmaceutical include Avidity Biosciences (RNA), Arcellx (ACLX), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), Akero Therapeutics (AKRO), Merus (MRUS), MorphoSys (MOR), Scholar Rock (SRRK), Protagonist Therapeutics (PTGX), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry. Collegium Pharmaceutical vs. Avidity Biosciences Arcellx Ultragenyx Pharmaceutical Zai Lab Akero Therapeutics Merus MorphoSys Scholar Rock Protagonist Therapeutics Crinetics Pharmaceuticals Collegium Pharmaceutical (NASDAQ:COLL) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, community ranking, earnings and media sentiment. Which has higher earnings and valuation, COLL or RNA? Collegium Pharmaceutical has higher revenue and earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCollegium Pharmaceutical$631.45M1.36$48.15M$1.8614.40Avidity Biosciences$10.90M340.22-$212.22M-$2.89-10.67 Does the media prefer COLL or RNA? In the previous week, Avidity Biosciences had 3 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 11 mentions for Avidity Biosciences and 8 mentions for Collegium Pharmaceutical. Avidity Biosciences' average media sentiment score of 1.51 beat Collegium Pharmaceutical's score of 0.94 indicating that Avidity Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avidity Biosciences 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more volatility & risk, COLL or RNA? Collegium Pharmaceutical has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Does the MarketBeat Community favor COLL or RNA? Collegium Pharmaceutical received 223 more outperform votes than Avidity Biosciences when rated by MarketBeat users. However, 69.14% of users gave Avidity Biosciences an outperform vote while only 65.49% of users gave Collegium Pharmaceutical an outperform vote. CompanyUnderperformOutperformCollegium PharmaceuticalOutperform Votes39165.49% Underperform Votes20634.51% Avidity BiosciencesOutperform Votes16869.14% Underperform Votes7530.86% Do analysts recommend COLL or RNA? Collegium Pharmaceutical presently has a consensus price target of $43.60, indicating a potential upside of 62.75%. Avidity Biosciences has a consensus price target of $66.69, indicating a potential upside of 116.25%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Avidity Biosciences is more favorable than Collegium Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Collegium Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is COLL or RNA more profitable? Collegium Pharmaceutical has a net margin of 14.78% compared to Avidity Biosciences' net margin of -2,772.45%. Collegium Pharmaceutical's return on equity of 104.67% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Collegium Pharmaceutical14.78% 104.67% 18.38% Avidity Biosciences -2,772.45%-27.66%-24.56% SummaryCollegium Pharmaceutical and Avidity Biosciences tied by winning 8 of the 16 factors compared between the two stocks. Get Collegium Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COLL vs. The Competition Export to ExcelMetricCollegium PharmaceuticalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$860.82M$6.70B$5.46B$7.81BDividend YieldN/A3.16%5.43%4.26%P/E Ratio11.557.2322.4318.45Price / Sales1.36239.68391.42101.46Price / Cash2.7665.8538.1834.62Price / Book4.476.306.684.19Net Income$48.15M$143.17M$3.22B$248.05M7 Day Performance-0.81%8.00%6.25%6.54%1 Month Performance-9.37%-4.01%-2.70%-1.97%1 Year Performance-26.44%-2.24%16.86%4.72% Collegium Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COLLCollegium Pharmaceutical3.9182 of 5 stars$26.79+0.0%$43.60+62.7%-26.4%$860.82M$631.45M11.55210Positive NewsRNAAvidity Biosciences2.8167 of 5 stars$28.52+7.0%$66.69+133.8%+26.6%$3.43B$10.90M-9.90190News CoveragePositive NewsACLXArcellx1.8713 of 5 stars$60.93-1.8%$110.67+81.6%+22.7%$3.35B$107.94M-85.8280News CoveragePositive NewsGap DownRAREUltragenyx Pharmaceutical4.2339 of 5 stars$35.40-0.8%$92.79+162.1%-13.9%$3.32B$560.23M-5.581,310Upcoming EarningsShort Interest ↑News CoverageZLABZai Lab2.1481 of 5 stars$29.71+3.0%$47.37+59.4%+101.1%$3.26B$398.99M-10.731,950Analyst RevisionNews CoverageAKROAkero Therapeutics4.1728 of 5 stars$37.67+0.1%$76.29+102.5%+107.7%$3.00BN/A-10.0530Positive NewsMRUSMerus3.4289 of 5 stars$43.23+0.4%$85.31+97.3%-3.3%$2.99B$36.13M-10.9437Short Interest ↓Positive NewsGap UpMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730SRRKScholar Rock4.0546 of 5 stars$29.81-3.1%$42.67+43.1%+125.8%$2.83B$33.19M-12.69140News CoveragePositive NewsPTGXProtagonist Therapeutics3.4252 of 5 stars$45.80-1.0%$65.44+42.9%+76.9%$2.81B$434.43M17.22120News CoveragePositive NewsCRNXCrinetics Pharmaceuticals3.647 of 5 stars$30.15-0.9%$73.00+142.1%-23.1%$2.81B$1.04M-8.08210News CoveragePositive News Related Companies and Tools Related Companies RNA Competitors ACLX Competitors RARE Competitors ZLAB Competitors AKRO Competitors MRUS Competitors MOR Competitors SRRK Competitors PTGX Competitors CRNX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COLL) was last updated on 4/27/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Collegium Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy COLL Stock Free COLL Stock Alerts